PUBLISHER: The Business Research Company | PRODUCT CODE: 1957562
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957562
Over-the-counter drugs are medications available for purchase without a prescription from a healthcare provider. These drugs are regarded as safe and effective for use by the general public when taken according to the directions on the label. They are commonly used to address minor health conditions and symptoms, including headaches, colds, allergies, pain, and digestive problems.
The primary types of over-the-counter (OTC) drugs include cough, cold, and flu products, analgesics, dermatology products, gastrointestinal products, vitamins, minerals, and supplements (VMS), weight loss or dietary products, ophthalmic products, sleeping aids, and others. Cough, cold, and flu products are medications designed to relieve symptoms related to respiratory infections, such as coughing, congestion, and fever. These medications come in various forms, including tablets, liquids, ointments, and sprays. They are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are utilized by a range of end-users, primarily specialty clinics, homecare, hospitals, and others.
Tariffs have influenced the OTC drugs market by increasing costs for imported active pharmaceutical ingredients, excipients, and packaging materials, impacting price-sensitive product categories such as analgesics and cold and flu remedies. Regions with high dependence on global supply chains, including Asia-Pacific and parts of North America, are most affected. These cost pressures have encouraged manufacturers to optimize formulations and sourcing strategies. At the same time, tariffs have supported domestic manufacturing, private-label growth, and local supply chain strengthening, creating long-term market opportunities.
The over the counter (otc) drugs market research report is one of a series of new reports from The Business Research Company that provides over the counter (otc) drugs market statistics, including over the counter (otc) drugs industry global market size, regional shares, competitors with a over the counter (otc) drugs market share, detailed over the counter (otc) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the over the counter (otc) drugs industry. This over the counter (otc) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The over the counter (otc) drugs market size has grown strongly in recent years. It will grow from $167.2 billion in 2025 to $176.48 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to wide availability of non-prescription medicines, strong retail pharmacy penetration, rising incidence of minor illnesses, increasing consumer health awareness, cost-effectiveness compared to prescription drugs.
The over the counter (otc) drugs market size is expected to see strong growth in the next few years. It will grow to $216.97 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to growth of online pharmacy channels, rising aging population with chronic minor ailments, increasing healthcare costs driving self-care, demand for convenient and fast-acting remedies, innovation in otc formulations and delivery forms. Major trends in the forecast period include growing preference for self-medication and preventive care, rising demand for natural and herbal otc products, expansion of private label and store brand otc drugs, increased focus on consumer-friendly packaging and labeling, growth of multi-symptom and combination otc products.
The increasing prevalence of lifestyle-related health conditions is anticipated to drive the expansion of the over-the-counter (OTC) drugs market in the coming years. Lifestyle-related health conditions refer to illnesses influenced by behaviors such as insufficient physical activity, poor dietary habits, smoking, excessive alcohol use, and chronic stress, all of which contribute to metabolic disorders and the development of chronic diseases. The rise in these conditions is fueled by rapid urbanization, sedentary lifestyles, and widespread availability of calorie-dense foods, leading to a growing dependence on convenient and accessible treatments for symptom relief. OTC drugs play a role in supporting public health by providing immediate, cost-effective options for managing conditions associated with obesity, diabetes, and metabolic risks, thereby alleviating pressure on formal healthcare systems. For example, in June 2024, according to the National Health Service, a UK-based government body, over half a million (549,000) additional individuals in England were identified in 2023 as being at risk of developing type 2 diabetes. This brought the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330, representing a notable increase from 3,065,825 in 2022, reflecting a rise of nearly 20%. Consequently, the growing prevalence of lifestyle-related diseases is contributing to the growth of the OTC drugs market.
Major companies in the over-the-counter (OTC) drug market are concentrating on developing user-friendly, spray-based emergency treatments such as OTC naloxone nasal sprays to enhance accessibility, enable rapid intervention, and improve public health outcomes. OTC naloxone sprays are formulated to provide fast-acting opioid overdose reversal without a prescription, allowing wider community use and timely emergency response. For example, in April 2024, Amneal Pharmaceuticals, Inc., a U.S.-based generic pharmaceutical company, received U.S. FDA approval for its OTC Naloxone Hydrochloride (4 mg) Nasal Spray, the first generic version of the OTC Narcan nasal spray. Intended for straightforward intranasal administration, the product offers a vital tool to reduce opioid-related deaths and expand nationwide access to life-saving overdose-reversal medications.
In July 2024, Cooper Consumer Health S.A., a France-based over-the-counter drug manufacturer, completed the acquisition of the OTC business of Viatris Inc. for an undisclosed sum. Through this acquisition, Cooper intends to broaden its consumer health portfolio by incorporating Viatris' well-established over-the-counter brands and enhancing its commercial presence across major European markets. Viatris Inc. is a US-based healthcare company that provided a diversified range of OTC products across various therapeutic categories.
Major companies operating in the over the counter (otc) drugs market are Pfizer Inc., Johnson & Johnson Private Limited, The Procter & Gamble Company, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Ltd., Reckitt Benckiser Group PLC, Viatris Inc., Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY LIMITED, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Perrigo Company plc, Cipla Inc., Dr. Reddy's Laboratories Ltd., Alkem Laboratories Limited, Piramal Enterprises Ltd
North America was the largest region in the over the counter (OTC) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the over the counter (otc) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the over the counter (otc) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The over-the-counter (OTC) drugs market consists of sales of pain relievers, allergy medications, first aid supplies, anti-diarrheal medications, and nasal sprays. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Over The Counter (OTC) Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses over the counter (otc) drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for over the counter (otc) drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The over the counter (otc) drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.